DXCM Stock Analysis: DexCom | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 30.162m USD | 12M Return: 42.5% | US2521311074 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 380M
EPS Trend: 90.1%
Qual. Beats: 3
Rev. Trend: 99.4%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DexCom, Inc. (NASDAQ: DXCM) is a U.S.-based medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health management, with operations in the United States and international markets. Its product portfolio includes the Dexcom G7 and G7 15 Day, Dexcom G6, Dexcom ONE+, the Stelo biosensor for adults with prediabetes and Type 2 diabetes not using insulin, as well as the Dexcom Share remote monitoring system and the Dexcom Follow mobile application. DexCom sells its products primarily through direct channels targeting endocrinologists, physicians, and diabetes educators. The company is incorporated in 1999, headquartered in San Diego, California, and has been listed on the NASDAQ since its IPO in April 2005, operating within the GICS Health Care Equipment sub-industry.
- Stelo biosensor expands into Type 2 diabetes market
- Abbott Libre competition pressures CGM market share and pricing
- International revenue growth offsets US volume and pricing pressure
| Net Income: 991.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 3.45 > 1.0 |
| NWC/Revenue: 32.59% < 20% (prev 41.71%; Δ -9.12% < -1%) |
| CFO/TA 0.23 > 3% & CFO 1.41b > Net Income 991.0m |
| Net Debt (-275.8m) to EBITDA (1.55b): -0.18 < 3 |
| Current Ratio: 1.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (383.5m) vs 12m ago -5.87% < -2% |
| Gross Margin: 63.42% > 18% (prev 59.01%; Δ 4.41% > 0.5%) |
| Asset Turnover: 74.31% > 50% (prev 60.21%; Δ 14.09% > 0%) |
| Interest Coverage Ratio: 95.21 > 6 (EBIT TTM 1.28b / Interest Expense TTM 13.4m) |
| A: 0.27 (Total Current Assets 3.92b - Total Current Liabilities 2.25b) / Total Assets 6.24b |
| B: 0.51 (Retained Earnings 3.16b / Total Assets 6.24b) |
| C: 0.19 (EBIT TTM 1.28b / Avg Total Assets 6.87b) |
| D: 0.68 (Book Value of Equity 2.54b / Total Liabilities 3.70b) |
| Altman-Z'' = 5.37 = AAA |
| DSRI: 0.90 (Receivables 1.19b/1.17b, Revenue 5.10b/4.52b) |
| GMI: 0.93 (GM 59.01% / 63.42%) |
| AQI: 1.11 (AQ_t 0.11 / AQ_t-1 0.10) |
| SGI: 1.13 (Revenue 5.10b / 4.52b) |
| TATA: -0.07 (NI 991.0m - CFO 1.41b) / TA 6.24b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of November 06, 2026, the stock is trading at USD 84.46 with a total of 4,899,646 shares traded. Over the past week, the price has changed by +5.67%, over one month by -2.81%, over three months by +2.18% and over the past year by +42.48%.
Current recommended Stop Loss: 80.30 (which is 4.9% or 1.5 ATR below the current price).
DexCom has received a consensus analysts rating of 4.66. Therefore, it is recommended to buy DXCM.
- StrongBuy: 22
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 96.2 | 13.9% |
P/E Trailing = 31.7183
P/E Forward = 25.3165
P/S = 6.0699
P/B = 11.3177
P/EG = 1.3018
Revenue TTM = 5.10b USD
EBIT TTM = 1.28b USD
EBITDA TTM = 1.55b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 20.7m USD (from shortTermDebt, last quarter)
Debt = 1.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 149.2m
Net Debt = -275.8m USD (calculated: Debt 1.54b - CCE 1.82b)
Enterprise Value = 29.9b USD (30.2b + Debt 1.54b - CCE 1.82b)
Interest Coverage Ratio = 95.21 (Ebit TTM 1.28b / Interest Expense TTM 13.4m)
EV/FCF = 27.21x (Enterprise Value 29.9b / FCF TTM 1.10b)
FCF Yield = 3.67% (FCF TTM 1.10b / Enterprise Value 29.9b)
FCF Margin = 21.52% (FCF TTM 1.10b / Revenue TTM 5.10b)
Net Margin = 19.41% (Net Income TTM 991.0m / Revenue TTM 5.10b)
Gross Margin = 63.42% ((Revenue TTM 5.10b - Cost of Revenue TTM 1.87b) / Revenue TTM)
Gross Margin QoQ = 64.29% (prev 63.44%)
Tobins Q-Ratio = 4.79 (Enterprise Value 29.9b / Total Assets 6.24b)
Interest Expense / Debt = 0.87% (Interest Expense 13.4m / Debt 1.54b)
Taxrate = 21.50% (271.4m / 1.26b)
NOPAT = 1.00b (EBIT 1.28b * (1 - 21.50%))
Current Ratio = 1.74 (Total Current Assets 3.92b / Total Current Liabilities 2.25b)
Debt / Equity = 0.61 (Debt 1.54b / totalStockholderEquity, last quarter 2.54b)
Debt / EBITDA = -0.18 (Net Debt -275.8m / EBITDA 1.55b)
Debt / FCF = -0.25 (Net Debt -275.8m / FCF TTM 1.10b)
Total Stockholder Equity = 2.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.43% (Net Income 991.0m / Total Assets 6.24b)
RoE = 36.50% (Net Income TTM 991.0m / Total Stockholder Equity 2.71b)
RoCE = 32.23% (EBIT 1.28b / Capital Employed (Equity 2.71b + L.T.Debt 1.24b))
RoIC = 26.70% (NOPAT 1.00b / Invested Capital 3.75b)
WACC = 8.22% (E(30.2b)/V(31.7b) * Re(8.61%) + D(1.54b)/V(31.7b) * Rd(0.87%) * (1-Tc(0.21)))
Discount Rate = 8.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.95 | Cagr: -3.63%
[DCF] Terminal Value 75.88% ; FCFF base≈1.08b ; Y1≈1.12b ; Y5≈1.25b
[DCF] Fair Price = 52.12 (EV 19.4b - Net Debt -275.8m = Equity 19.7b / Shares 377.4m; r=8.35% [WACC [floored]]; 5y FCF grow 3.43% → 2.50% )
EPS Correlation: 90.13 | EPS CAGR: 20.88% | SUE: 1.49 | # QB: 3
Revenue Correlation: 99.37 | Revenue CAGR: 13.10% | SUE: 1.69 | # QB: 3
EPS current Year (2026-12-31): EPS=2.67 | Chg30d=+0.02% | Revisions=+0% | GrowthEPS=+27.5% | GrowthRev=+12.1%
EPS next Year (2027-12-31): EPS=3.13 | Chg30d=-0.02% | Revisions=-40% | GrowthEPS=+17.3% | GrowthRev=+10.8%
[Analyst] Revisions Ratio: -29% (up=1, down=3)